ICCMIcecure Medical Ltd
ICCM
Icecure Medical Ltd2,850
Mkt Cap
$39.24MVolume
131,901.0052W High
$1.5352W Low
$0.5401PE Ratio
-2.24ICCM Fundamentals
Price
$0.5712Prev Close
$0.5796Open
$0.6050D MA
$0.6379Beta
0.65Avg. Volume
252,632.75EPS (Annual)
-$0.2954P/B
4.23Rev/Employee
$45,708.33$48.86
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 IceCure Medical Successfully Completes...
PR Newswire·45m ago
IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation
IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation IceCure Announces Thomas Hospital of Infirmary Health...
PR Newswire·4d ago
IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense
IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation...
PR Newswire·12d ago
IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved
IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones...
PR Newswire·14d ago
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025...
PR Newswire·1mo ago
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense Cryoablation for Low-Risk Breast Cancer
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense Cryoablation for Low-Risk Breast Cancer IceCure Expected to Report Record Fourth...
PR Newswire·2mo ago
IceCure's ProSense Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
IceCure's ProSense Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting IceCure's ProSense Cryoablation Featured in 4...
PR Newswire·3mo ago
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes IceCure Receives Notice of Patent Allowance in China for a Novel...
PR Newswire·3mo ago
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 PR Newswire...
PR Newswire·3mo ago
IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer IceCure's ProSense Cryoablation System Receives...
PR Newswire·3mo ago
<
1
2
...
>